Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple System Atrophy (MSA): early-phase trial registry
1 of 3 indexed Multiple System Atrophy (MSA) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Multiple System Atrophy (MSA): 3 US clinical trials tracked, 1 recruiting.
Multiple System Atrophy (MSA) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Ono Pharmaceutical Co., running 1 of these trials.
Enrollment posture brief
Registry condition multiple-system-atrophy-msa
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Multiple System Atrophy (MSA) lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple System Atrophy (MSA) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple System Atrophy (MSA) is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Multiple System Atrophy Multidisciplinary Clinic
University of Texas Southwestern Medical Center
NCT03811808
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
Ono Pharmaceutical Co.
NCT05923866
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
AstraZeneca
NCT02388295
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple System Atrophy (MSA) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple System Atrophy (MSA) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple System Atrophy (MSA) page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Multiple System Atrophy (MSA) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Ono Pharmaceutical Co. sponsors the most Multiple System Atrophy (MSA) trials on record, review their full trial history before evaluating a specific study. See Ono Pharmaceutical Co.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple System Atrophy (MSA) condition card totals 3 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.